MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company s Psychedelic Digital Therapeutics Technology Platform
News provided by
Share this article
Share this article
Utilizing Speak Ai s technology, iSTRYM will provide Ai-driven intelligence to help therapists identify the most efficient and efficacious outcomes for patients of psychedelic assisted psychotherapy
VANCOUVER, BC, April 13, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( MINDCURE or the Company ) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce that it has entered into a partnership with Speak Ai Inc. ( Speak Ai ). The Canadian-based technology company helps individuals and organizations analyze media, language, and metadata to automatically generate valuable insights through machine learning. MINDCURE will be integrating the platform s capabilities into iSTRYM, and will also work with Speak Ai to develop prop
Korona, FHI | Store variasjonar nasjonalt – gjenopninga kan bli delt opp, trur FHI-topp
sognavis.no - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sognavis.no Daily Mail and Mail on Sunday newspapers.
How This App Can Play a Role in the Psychedelics Industry
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
Korona, Oslo | Store variasjonar nasjonalt – gjenopninga kan bli delt opp, trur FHI-topp
firda.no - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from firda.no Daily Mail and Mail on Sunday newspapers.
The candidates are:
MYCO – 001: a form of pure psilocybin derived from natural fungal sources, targeted to be used at mid-to-late-stage clinical trials.
MYCO – 002: an empathogen with similar effects to MDMA that could have an improved safety profile.
MYCO – 003: a psilocybin-based formula that could diminish the possibility of bad experiences by reducing patient anxiety.
MYCO – 004: a hallucinogen delivered transdermally, offering precision dosing and long-term compound stability.
The claims presented for these compounds need to be proven in clinical trials and via further research.
“By increasing the complexity of these compounds, we are increasing layers of patents applied, which in turn, also adds pharmaceutical value to the drug candidates,” said Joshua Bartch, co-founder and CEO of Mydecine.